What's new? Log in Free sign up

Blueprint Medicines (BPMC) News and press releases

Company Profile

News

From Benzinga Pro

Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.

EPAM Systems, Amyris, Blueprint Medicines And Other Big Stocks Moving Lower On Monday

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded mixed, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording losses in today’s session.

Benzinga's Top Ratings Upgrades, Downgrades For June 5, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

US Stocks Mixed; SAIC Posts Upbeat Results

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas

U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to 13,251.38. The S&P 500, also rose, gaining, 0.13% to 4,288.00.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday

News, Price Target, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas

BMO Capital boosted the price target for Equity Residential (NYSE: EQR) from $60 to $64. BMO Capital analyst John Kim upgraded the stock from Underperform to Market Perform. Equity Residential shares rose 0.7% to $63.56 in pre-market trading.

SVB Leerink Downgrades Blueprint Medicines to Underperform, Lowers Price Target to $43

News, Downgrades, Price Target, Analyst Ratings

SVB Leerink analyst Andrew Berens downgrades Blueprint Medicines (NASDAQ:BPMC) from Market Perform to Underperform and lowers the price target from $48 to $43.

Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future

Analyst Color, Biotech, News, Health Care, Price Target, Reiteration, Analyst Ratings, Movers, Trading Ideas, General

Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for

FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients

Biotech, News, Health Care, FDA, Movers, Trading Ideas, General

Analyst Expectations for Blueprint Medicines's Future

Analyst Ratings

Guggenheim Maintains Buy on Blueprint Medicines, Raises Price Target to $82

News, Price Target, Analyst Ratings

Guggenheim analyst Michael Schmidt maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $78 to $82.

Wedbush Reiterates Outperform on Blueprint Medicines, Maintains $75 Price Target

News, Price Target, Reiteration, Analyst Ratings

Wedbush analyst Liana Moussatos reiterates Blueprint Medicines (NASDAQ:BPMC) with a Outperform and maintains $75 price target.

JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target

News, Price Target, Reiteration, Analyst Ratings

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $114 price target.

Wells Fargo Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $48

News, Price Target, Analyst Ratings

Wells Fargo analyst Derek Archila maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $47 to $48.

HC Wainwright & Co. Maintains Buy on Blueprint Medicines, Raises Price Target to $85

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Andrew Fein maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $75 to $85.

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $67

News, Price Target, Analyst Ratings

Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $65 to $67.

Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $46

News, Price Target, Analyst Ratings

Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $44 to $46.

Blueprint Medicines's Return On Capital Employed Overview

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $55

News, Price Target, Analyst Ratings

Morgan Stanley analyst Michael Ulz maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $50 to $55.

Analyst Ratings for Blueprint Medicines

Analyst Ratings

Press releases

From Benzinga Pro

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), today announced that, effective June 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

-- Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs -- CAMBRIDGE, Mass., June 3, 2023 /PRNewswire/ -- Blueprint

NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis

-- First and only treatment approved by FDA for indolent SM -- CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that NEJM Evidence, a journal from The New

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

-- For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief -- -- Approval based on the positive PIONEER trial, in

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that, effective May 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted

Blueprint Medicines Reports First Quarter 2023 Results

Earnings, Press Releases

-- Achieved $39.1 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues and $63.3 million in total revenues in the first quarter of 2023 -- -- Raising 2023 AYVAKIT net product revenue guidance to $135

Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting

CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023

Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

CAMBRIDGE, Mass., April 20, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023 to report its

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222

CAMBRIDGE, Mass., March 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase 1/2 VELA

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.